Patents by Inventor David KRYZA

David KRYZA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250041221
    Abstract: The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.
    Type: Application
    Filed: December 2, 2022
    Publication date: February 6, 2025
    Applicants: Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils De Lyon, INSERM (Institut National de la Santé et de la Recherche Médicale), Universita Degli Studi Di Verona
    Inventors: Giovanna Lollo, Valentina Andretto, David Kryza, Eyad Al Mouazen, Mathieu Repellin, Stéphanie Briancon, Laurent Schaeffer, Jacquier Arnaud, Laurent Coudert
  • Publication number: 20240342322
    Abstract: The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.
    Type: Application
    Filed: July 26, 2022
    Publication date: October 17, 2024
    Inventors: Mathieu RICHAUD, Jennifer WISCHHUSEN, David NEVES, Patrick MEHLEN, David SARRUT, Benjamin GIBERT, David KRYZA
  • Publication number: 20230381185
    Abstract: Described herein is a novel nanocomposite for oral administration for treatment of gastrointestinal disease, e.g., IBD, or injury. The nanocomposite contains nanoemulsion particles (NEs), loaded with an active therapeutic agent, that are then combined with a second component containing a self-assembling peptide(s) (SAP) or peptidomimetic(s) (optionally, the second component is in a powder form). Upon administration, when hydrated at slightly acidic or near-neutral pH, the system self-assembles into a hydrogel matrix enveloping NEs, which then adheres to, and more efficiently delivers, the active agent to the intestinal tract of a treated subject. The nanocomposite can be administered in a capsule dosage form that forms a depot in the stomach or post-stomach.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 30, 2023
    Applicants: 3-D Matrix, Ltd., UNIVERSITE CLAUDE BERNARD LYON 1, Hôpital Lyon Sud
    Inventors: Giovanna Lollo, Marie Reveiller Buffier, Sharanya Sankar, David Kryza, Annalisa Rosso, Vanentina Andretto, Stephane Nancey, Gilles Boschetti
  • Publication number: 20160221992
    Abstract: The invention relates to dendritic compounds comprising a chelating, fluorochrome or recognition agent of formula (I), to compositions comprising same, and to uses thereof, wherein in said formula (I): T, L1, D, R, L2, V and n are as defined in the description.
    Type: Application
    Filed: May 16, 2014
    Publication date: August 4, 2016
    Inventors: Delphine FELDER-FLESCH, Claire BILLOTEY, Audrey PARAT, Antonio GAROFALO, David KRYZA, Marc JANIER